Home » Topics » Disease categories and therapies » Substance use and poisoning

Substance use and poisoning
RSS

FDA grants priority review to RBP-6000 NDA, clearance for buprenorphine assay

Aug. 1, 2017

Pfizer discloses dopamine D3 receptor ligands

July 28, 2017

Opiant reports phase I data on OPNT-002

July 21, 2017

Rolling NDA submission completed for CAM-2038 to treat opioid use disorder

July 20, 2017

MMRF selects Avista Pharma to manufacture component of opioid addiction vaccine

July 14, 2017

FDA grants orphan drug designation to ResQ's LipidRescue

June 16, 2017

Fennec launches European Named Patient Program for sodium thiosulfate

May 31, 2017

Selecta initiates phase I trial of nicotine vaccine candidate SELA-070

May 15, 2017

Embera NeuroTherapeutics' EMB-001 well tolerated in phase Ib cocaine interaction study

May 9, 2017

Cleveland BioLabs updates entolimod progress

April 18, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 3, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...